Shoulder PainPhase 4PASSNCT02517437
Suprascapular and Axillary Blocks Versus Interscalene Block for Shoulder Surgery
A Phase 4 study testing Suprascapular & axillary blocks and Interscalene block in people with Shoulder Pain, run by University Health Network, Toronto at 2 sites in Canada.
Trial summary
The purpose of this study is to determine whether the combination of suprascapular and axillary nerve blocks is non-inferior to the conventional interscalene block (ISB) in providing pain relief during the first postoperative day to adult healthy patients (age > 18) undergoing ambulatory shoulder surgery. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Shoulder Pain
- What is being tested?
- Suprascapular & axillary blocks and Interscalene block
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 130 participants
- Where
- 2 sitesCanada
- Study dates
- Aug 2015to Jan 2018
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Consented, English-speaking, adult patients (age > 18)
- American Society of Anesthesiologists (ASA) classification I-III
- BMI ≤ 30 kg/m2
Who cannot join
- Total shoulder arthroplasty or clavicular surgery (ISB does not provide sufficient pain relief)
- Known broncho-pulmonary or phrenic pathology compromising respiratory function
- Contra-indication to nerve blocks e.g., infection, bleeding diathesis, allergy to local anesthetics
- Existing chronic pain disorders or history of use of ≥ 30mg oxycodone or equivalent per day
- Pre-existing neurological deficits or peripheral neuropathy involving the operative upper extremity
- Contraindication to any component of multi-modal analgesia (acetaminophen, non-steroidal anti-inflammatory medications, oral opioid analgesics)
- Pregnancy or any significant psychiatric conditions that may affect patient assessment
Trial locations and contacts
2 sites in 1 country.
Canada2 sites
Women's College Hospital
Toronto, Ontario, M5S 1B2
Toronto Western Hopspital
Toronto, Ontario, M5T2S8
About this study
Official title: Novel Combination of Suprascapular & Axillary Nerve Blocks Versus Conventional Interscalene Brachial Plexus Block for Pain Relief Following Shoulder Surgery: A Multi-centre Randomized, Patient & Assessor Blinded, Non-inferiority Trial
The purpose of this study is to determine whether the combination of suprascapular and axillary nerve blocks is non-inferior to the conventional interscalene block (ISB) in providing pain relief during the first postoperative day to adult healthy patients (age > 18) undergoing ambulatory shoulder surgery.
Read the detailed description
Study Hypothesis:The pain relief provided by a combination of suprascapular and axillary nerve blocks is non-inferior to that produced by the conventional interscalene block during the first 24hours postoperatively in adult patients undergoing ambulatory shoulder surgery.
Intervention and Comparator: Consented patients will be randomized to receive either pre-operative ISB (plus sham SAB with subcutaneous saline), or SAB (plus sham ISB). Both groups will receive general anesthesia for surgery.
Primary Aim: To demonstrate non-inferiority of pain relief produced by the combination treatment compared to the conventional treatment by comparing the area under the curve of the postoperative pain scores plot over time during the first 24 hours postoperatively.
Secondary Aims: There are four secondary aims, covering efficacy (analgesia) and safety: rest pain, quality of recovery, safety, other pain relief indicators.
Design There will be a multi-centre, prospective, randomized, patient and assessor blinded, two-arm, parallel-group, 1:1 allocation ratio, placebo-controlled, non-inferiority clinical trial comparing the effect of SAB treatment to conventional ISB treatment on pain relief during the first postoperative 24 hours in patients undergoing ambulatory shoulder surgery under general anesthesia.
Methods Study participants
The target population will be adult patients (age > 18) presenting for outpatient (same day surgery) unilateral arthroscopic or open shoulder surgery. Eligible surgical procedures are:
- Shoulder arthroscopy
- Shoulder instability procedures
- Superior labrum anterior posterior repair (SLAP)
- Rotator cuff repair
- Bankart repair
- Acromioplasty
Study centres The trial will be conducted at the two academic medical centres in Toronto where ambulatory shoulder surgery is routinely performed: Toronto Western Hospital (TWH),and Women's College Hospital (WCH).
Preoperative management Unless allergic, all patients will receive acetaminophen 1 gr and celecoxib 400 mg orally with sips of water one hour prior to surgery. All blocks will be performed in the block room one hour before surgery.
Suprascapular and axillary nerve blocks (SAB group) Patients allocated to the suprascapular and axillary nerve block combination (SAB group) will receive these blocks in the sitting position. The shoulder will be in the neutral position but rotated 45 degrees inward and the elbow flexed at 90 degrees while the hand rests on the knees. The suprascapular nerve will be blocked as it branches from the superior trunk.78After sterile skin preparation with chlorhexidine, a linear array transducer (6-13 MHz, Sonosite M-Turbo) probe protected by a 3M Tegaderm® dressing or a sterile sheath is placed in the transverse plane to visualize C5 and C6 roots in the interscalene groove. These roots are then traced distally to where they coalesce to form the superior trunk. The suprascapular nerve is then identified and as it emerges from the superior trunk, under the deep cervical fascia and superficial to the middle scalene muscle. After infiltration with 1 mL of 1% lidocaine, a 5 cm 22 G insulated needle (B. Braun Medical Inc., Bethlehem, PA, USA) is inserted in line with the probe in a lateral-to-medial orientation towards the nerve. Local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots after negative aspiration for blood to achieve circumferential spread around the nerve.
The axillary nerve block will be performed next in the posterior aspect of the operative arm. The US transducer is placed in the longitudinal plane, parallel to the long axis of the humerus shaft and approximately 2cm below the postero-lateral part of the acromion on the posterior aspect of the arm. (Figure 1) The neurovascular bundle encompassing the humeral artery, posterior circumflex artery, and axillary nerve is visualized in the lateral edge of the quadrangular space, deep to the deltoid muscle, inferior to the teres minor muscle, and superior to the triceps tendon. After infiltration with 1 mL of 1% lidocaine, the 22G needle is inserted in line with the probe in a caudad orientation towards the bundle. Local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots after negative aspiration to achieve circumferential spread around the bundle.
Finally, to maintain patient blinding, sham ISB block will be performed in the semi-sitting position using a 25G needle to inject 1 mL of lidocaine 1% subcutaneously.
Interscalene block (ISB group) Local anesthetic solution (20 mL of 0.5% ropivacaine) will be injected in 5 mL aliquots after negative aspiration for blood to achieve spread posterior to or between the C5 and C6 nerve roots. Subsequently, patients will receive sham SAB performed in the sitting position using a 25G needle to inject 1 mL of lidocaine 1% subcutaneously.
Block assessment Assessment of sensory block onset to confirm block success is done by the research assistant doing the blocks every 5 minutes, for 30 minutes, with a blunt 22G needle applied to skin, by comparing to the contralateral upper extremity.
General anesthesia All patients will receive a standardized general anesthetic.
Postoperative management Discharged patients will receive a prescription for Tylenol #3® as needed, or Percocet® if intolerant to codeine.
Two-week follow-up A study follow-up phone call will be arranged to specifically assess any potential block-related neurologic symptoms such as pain, paresthesia, dysesthesia, sensory loss, motor power weakness. Patients found to have such symptoms will be offered a referral to the chronic pain clinic at TWH for assessment and management.
Data collection The study coordinators of the participating sites will use a paper-based case report form (CRF) prepared by the principal investigator for documentation of outcome results. Subject confidentiality will be maintained by using a study ID (not related to name, or date of birth) on all CRFs.
Sample Size Investigators aim to enroll a total of 65 patients per group, or a total of 130 patients. Based on the annual number of shoulder surgeries performed at each centre, the researchers plan to recruit 45 patients at TWH, and another 85 patients at WCH.
Source Data Verification: Patient Electronic Record
Quality Assurance \& Data Checks: N/A
- Conditions
- Shoulder Pain
- Being tested
- Suprascapular & axillary blocks, Interscalene block
- Medical subject headings
- Shoulder Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Suprascapular & axillary blocksDrug
Also called Suprascapular and axillary blocks
After infiltration with 1 mL of 1% lidocaine, local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots to achieve circumferential spread around the nerve.The axillary nerve block will be performed next in the posterior aspect of the operative arm. The neurovascular bundle encompassing the humeral artery, posterior circumflex artery, and axillary nerve is visualized in the lateral edge of the quadrangular space, deep to the deltoid muscle, inferior to the teres minor muscle, and superior to the triceps tendon. After infiltration with 1 mL of 1% lidocaine, local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots after negative aspiration to achieve circumferential spread around the bundle.
Interscalene blockDrug
After sterile skin preparation with chlorhexidine and infiltration with 1 mL of 1% lidocaine, a 5 cm 22 G insulated needle is then inserted and local anesthetic solution (20 mL of 0.5% ropivacaine) will be injected in 5 mL aliquots after negative aspiration for blood to achieve spread posterior to or between the C5 and C6 nerve roots.
| Study group | Role | What they receive |
|---|---|---|
| Suprascapular & axillary blocks | Active comparator | Suprascapular and axillary blocks. Receives: Drug: Suprascapular & axillary blocks |
| Interscalene block | Active comparator | Interscalene block. Receives: Drug: Interscalene block |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postoperative pain severity
Numeric rating scale (NRS) scores will be evaluated by blinded study coordinators who are not involved in patient care.
Measured: 1st post-operative 24 hours
Secondary outcomes (2)
Rest pain at additional time points
Measured: 0, 6, 12, 18, and 24 hours postoperatively
Quality of Recovery (QoR)
The impact of surgical and anesthetic interventions on perioperative quality of life and ability to resume routine life activities will be assessed using the Quality of Recovery (QoR) tool. The QoR-15 scale is a patient-based outcome measure in the form of a 15-item validated questionnaire.
Measured: 24 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Aug 2015 (estimated)
- Study startAug 2015
- Primary completionJan 2018
- Study completionJan 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Shoulder PainStudies of the same condition, open and under way.
- More trials run by University Health Network, TorontoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 130 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Health Network, Toronto
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Vincent Chan, MD, Principal investigator, Toronto Western Hospital, University Health Network, University of TorontoFaraj Abdallah, MD, Principal investigator, St. Michael's Hospital, University of TorontoRichard Brull, MD, Principal investigator, Women's College Hospital, University of Toronto
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02517437
- Sponsor's protocol ID
- REB14-8557-A
- Acronym
- PASS
- Status last verified
- Mar 2018
- First submitted
- 20 Jul 2015
- Last updated
- 31 May 2018
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- Yes: publication
Publications
Stark PA, Myles PS, Burke JA. Development and psychometric evaluation of a postoperative quality of recovery score: the QoR-15. Anesthesiology. 2013 Jun;118(6):1332-40. doi: 10.1097/ALN.0b013e318289b84b.
PubMed 23411725Voogd AC, Ververs JM, Vingerhoets AJ, Roumen RM, Coebergh JW, Crommelin MA. Lymphoedema and reduced shoulder function as indicators of quality of life after axillary lymph node dissection for invasive breast cancer. Br J Surg. 2003 Jan;90(1):76-81. doi: 10.1002/bjs.4010.
PubMed 12520579Peintinger F, Reitsamer R, Stranzl H, Ralph G. Comparison of quality of life and arm complaints after axillary lymph node dissection vs sentinel lymph node biopsy in breast cancer patients. Br J Cancer. 2003 Aug 18;89(4):648-52. doi: 10.1038/sj.bjc.6601150.
PubMed 12915872Lo IK, Litchfield RB, Griffin S, Faber K, Patterson SD, Kirkley A. Quality-of-life outcome following hemiarthroplasty or total shoulder arthroplasty in patients with osteoarthritis. A prospective, randomized trial. J Bone Joint Surg Am. 2005 Oct;87(10):2178-85. doi: 10.2106/JBJS.D.02198.
PubMed 16203880Gutierrez DD, Thompson L, Kemp B, Mulroy SJ; Physical Therapy Clinical Research Network; Rehabilitation Research and Training Center on Aging-Related Changes in Impairment for Persons Living with Physical Disabilities. The relationship of shoulder pain intensity to quality of life, physical activity, and community participation in persons with paraplegia. J Spinal Cord Med. 2007;30(3):251-5. doi: 10.1080/10790268.2007.11753933.
PubMed 17684891
Study at a glance
From the registry record, last updated by the sponsor on 31 May 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Novel Combination of Suprascapular & Axillary Nerve Blocks Versus Conventional Interscalene Brachial Plexus Block for Pain Relief Following Shoulder Surgery: A Multi-centre Randomized, Patient & Assessor Blinded, Non-inferiority Trial
- ClinicalTrials.gov ID
- NCT02517437
- Acronym / sponsor ID
- PASS / REB14-8557-A
- Conditions
- Shoulder Pain
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 130 participants (actual)
- Lead sponsor
- University Health Network, TorontoUniversity, hospital or other
- Study start
- Aug 2015
- Primary completion
- Jan 2018 (actual)
- Study completion
- Jan 2018 (actual)
- First posted
- 7 Aug 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine whether the combination of suprascapular and axillary nerve blocks is non-inferior to the conventional interscalene block (ISB) in providing pain relief during the first postoperative day to adult healthy patients (age > 18) undergoing ambulatory shoulder surgery.
Detailed description
Study Hypothesis:The pain relief provided by a combination of suprascapular and axillary nerve blocks is non-inferior to that produced by the conventional interscalene block during the first 24hours postoperatively in adult patients undergoing ambulatory shoulder surgery.
Intervention and Comparator: Consented patients will be randomized to receive either pre-operative ISB (plus sham SAB with subcutaneous saline), or SAB (plus sham ISB). Both groups will receive general anesthesia for surgery.
Primary Aim: To demonstrate non-inferiority of pain relief produced by the combination treatment compared to the conventional treatment by comparing the area under the curve of the postoperative pain scores plot over time during the first 24 hours postoperatively.
Secondary Aims: There are four secondary aims, covering efficacy (analgesia) and safety: rest pain, quality of recovery, safety, other pain relief indicators.
Design There will be a multi-centre, prospective, randomized, patient and assessor blinded, two-arm, parallel-group, 1:1 allocation ratio, placebo-controlled, non-inferiority clinical trial comparing the effect of SAB treatment to conventional ISB treatment on pain relief during the first postoperative 24 hours in patients undergoing ambulatory shoulder surgery under general anesthesia.
Methods Study participants
The target population will be adult patients (age > 18) presenting for outpatient (same day surgery) unilateral arthroscopic or open shoulder surgery. Eligible surgical procedures are:
- Shoulder arthroscopy
- Shoulder instability procedures
- Superior labrum anterior posterior repair (SLAP)
- Rotator cuff repair
- Bankart repair
- Acromioplasty
Study centres The trial will be conducted at the two academic medical centres in Toronto where ambulatory shoulder surgery is routinely performed: Toronto Western Hospital (TWH),and Women's College Hospital (WCH).
Preoperative management Unless allergic, all patients will receive acetaminophen 1 gr and celecoxib 400 mg orally with sips of water one hour prior to surgery. All blocks will be performed in the block room one hour before surgery.
Suprascapular and axillary nerve blocks (SAB group) Patients allocated to the suprascapular and axillary nerve block combination (SAB group) will receive these blocks in the sitting position. The shoulder will be in the neutral position but rotated 45 degrees inward and the elbow flexed at 90 degrees while the hand rests on the knees. The suprascapular nerve will be blocked as it branches from the superior trunk.78After sterile skin preparation with chlorhexidine, a linear array transducer (6-13 MHz, Sonosite M-Turbo) probe protected by a 3M Tegaderm® dressing or a sterile sheath is placed in the transverse plane to visualize C5 and C6 roots in the interscalene groove. These roots are then traced distally to where they coalesce to form the superior trunk. The suprascapular nerve is then identified and as it emerges from the superior trunk, under the deep cervical fascia and superficial to the middle scalene muscle. After infiltration with 1 mL of 1% lidocaine, a 5 cm 22 G insulated needle (B. Braun Medical Inc., Bethlehem, PA, USA) is inserted in line with the probe in a lateral-to-medial orientation towards the nerve. Local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots after negative aspiration for blood to achieve circumferential spread around the nerve.
The axillary nerve block will be performed next in the posterior aspect of the operative arm. The US transducer is placed in the longitudinal plane, parallel to the long axis of the humerus shaft and approximately 2cm below the postero-lateral part of the acromion on the posterior aspect of the arm. (Figure 1) The neurovascular bundle encompassing the humeral artery, posterior circumflex artery, and axillary nerve is visualized in the lateral edge of the quadrangular space, deep to the deltoid muscle, inferior to the teres minor muscle, and superior to the triceps tendon. After infiltration with 1 mL of 1% lidocaine, the 22G needle is inserted in line with the probe in a caudad orientation towards the bundle. Local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots after negative aspiration to achieve circumferential spread around the bundle.
Finally, to maintain patient blinding, sham ISB block will be performed in the semi-sitting position using a 25G needle to inject 1 mL of lidocaine 1% subcutaneously.
Interscalene block (ISB group) Local anesthetic solution (20 mL of 0.5% ropivacaine) will be injected in 5 mL aliquots after negative aspiration for blood to achieve spread posterior to or between the C5 and C6 nerve roots. Subsequently, patients will receive sham SAB performed in the sitting position using a 25G needle to inject 1 mL of lidocaine 1% subcutaneously.
Block assessment Assessment of sensory block onset to confirm block success is done by the research assistant doing the blocks every 5 minutes, for 30 minutes, with a blunt 22G needle applied to skin, by comparing to the contralateral upper extremity.
General anesthesia All patients will receive a standardized general anesthetic.
Postoperative management Discharged patients will receive a prescription for Tylenol #3® as needed, or Percocet® if intolerant to codeine.
Two-week follow-up A study follow-up phone call will be arranged to specifically assess any potential block-related neurologic symptoms such as pain, paresthesia, dysesthesia, sensory loss, motor power weakness. Patients found to have such symptoms will be offered a referral to the chronic pain clinic at TWH for assessment and management.
Data collection The study coordinators of the participating sites will use a paper-based case report form (CRF) prepared by the principal investigator for documentation of outcome results. Subject confidentiality will be maintained by using a study ID (not related to name, or date of birth) on all CRFs.
Sample Size Investigators aim to enroll a total of 65 patients per group, or a total of 130 patients. Based on the annual number of shoulder surgeries performed at each centre, the researchers plan to recruit 45 patients at TWH, and another 85 patients at WCH.
Source Data Verification: Patient Electronic Record
Quality Assurance \& Data Checks: N/A
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Suprascapular & axillary blocks | Active comparator | Drug: Suprascapular & axillary blocksSuprascapular and axillary blocks. |
| Interscalene block | Active comparator | Drug: Interscalene blockInterscalene block. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Consented, English-speaking, adult patients (age > 18)
- American Society of Anesthesiologists (ASA) classification I-III
- BMI ≤ 30 kg/m2
Key exclusion criteria (7 listed)
- Total shoulder arthroplasty or clavicular surgery (ISB does not provide sufficient pain relief)
- Known broncho-pulmonary or phrenic pathology compromising respiratory function
- Contra-indication to nerve blocks e.g., infection, bleeding diathesis, allergy to local anesthetics
- Existing chronic pain disorders or history of use of ≥ 30mg oxycodone or equivalent per day
- Pre-existing neurological deficits or peripheral neuropathy involving the operative upper extremity
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Suprascapular & axillary blocksAlso: Suprascapular and axillary blocksAfter infiltration with 1 mL of 1% lidocaine, local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots to achieve circumferential spread around the nerve.The axillary nerve block will be performed next in the posterior aspect of the operative arm. The neurovascular bundle encompassing the humeral artery, posterior circumflex artery, and axillary nerve is visualized in the lateral edge of the quadrangular space, deep to the deltoid muscle, inferior to the teres minor muscle, and superior to the triceps tendon. After infiltration with 1 mL of 1% lidocaine, local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots after negative aspiration to achieve circumferential spread around the bundle. | Drug | Suprascapular & axillary blocks |
| Interscalene blockAfter sterile skin preparation with chlorhexidine and infiltration with 1 mL of 1% lidocaine, a 5 cm 22 G insulated needle is then inserted and local anesthetic solution (20 mL of 0.5% ropivacaine) will be injected in 5 mL aliquots after negative aspiration for blood to achieve spread posterior to or between the C5 and C6 nerve roots. | Drug | Interscalene block |
Primary outcome
Postoperative pain severity
Time frame: 1st post-operative 24 hours
Numeric rating scale (NRS) scores will be evaluated by blinded study coordinators who are not involved in patient care.
2 secondary outcomes
Rest pain at additional time points
Time frame: 0, 6, 12, 18, and 24 hours postoperatively
Quality of Recovery (QoR)
Time frame: 24 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 May 2018.
- Background: PubMed 23411725Stark PA, Myles PS, Burke JA. Development and psychometric evaluation of a postoperative quality of recovery score: the QoR-15. Anesthesiology. 2013 Jun;118(6):1332-40. doi: 10.1097/ALN.0b013e318289b84b.
- Background: PubMed 12520579Voogd AC, Ververs JM, Vingerhoets AJ, Roumen RM, Coebergh JW, Crommelin MA. Lymphoedema and reduced shoulder function as indicators of quality of life after axillary lymph node dissection for invasive breast cancer. Br J Surg. 2003 Jan;90(1):76-81. doi: 10.1002/bjs.4010.
- Background: PubMed 12915872Peintinger F, Reitsamer R, Stranzl H, Ralph G. Comparison of quality of life and arm complaints after axillary lymph node dissection vs sentinel lymph node biopsy in breast cancer patients. Br J Cancer. 2003 Aug 18;89(4):648-52. doi: 10.1038/sj.bjc.6601150.
- Background: PubMed 16203880Lo IK, Litchfield RB, Griffin S, Faber K, Patterson SD, Kirkley A. Quality-of-life outcome following hemiarthroplasty or total shoulder arthroplasty in patients with osteoarthritis. A prospective, randomized trial. J Bone Joint Surg Am. 2005 Oct;87(10):2178-85. doi: 10.2106/JBJS.D.02198.
- Background: PubMed 17684891Gutierrez DD, Thompson L, Kemp B, Mulroy SJ; Physical Therapy Clinical Research Network; Rehabilitation Research and Training Center on Aging-Related Changes in Impairment for Persons Living with Physical Disabilities. The relationship of shoulder pain intensity to quality of life, physical activity, and community participation in persons with paraplegia. J Spinal Cord Med. 2007;30(3):251-5. doi: 10.1080/10790268.2007.11753933.
- Individual participant dataSharing planned: Yes. publication
Related trials for Shoulder Pain
Recruiting
Effects of Cervicothoracic Mobilization in Patients With Supraspinatus Tendinitis
Rotator Cuff Tendonitis
Recruiting
Hybrid mHealth and Telerehabilitation vs Conventional Physiotherapy for Subacromial Pain Syndrome
Subacromial Pain Syndrome
Not yet recruiting
Magnesium Sulphate as an Adjuvant in Combined Costoclavicular Block and Suprascapular Block Versus Interscalene Block for Ambulatory Shoulder Arthroscopy
Postoperative Pain, Shoulder Arthroscopy
Active, not recruiting
Effects of Injection Combined With Spencer Technique on Painful Frozen Shoulder
Frozen Shoulder
Not yet recruiting
Laser Therapy Versus Transcutaneous Electical Nerve Stimulation at Hemiplegic Shoulder Pain
Hemiplegic Shoulder Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Vincent Chan, MD principal investigator
Toronto Western Hospital, University Health Network, University of Toronto
Faraj Abdallah, MD principal investigator
St. Michael's Hospital, University of Toronto
Richard Brull, MD principal investigator
Women's College Hospital, University of Toronto
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Suprascapular & axillary blocks and Interscalene block in people with Shoulder Pain, run by University Health Network, Toronto at 2 sites in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 May 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postoperative pain severity (time frame: 1st post-operative 24 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02517437, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 May 2018.